Bladder Cancer Trial, Recruiting NCT06689176 Sponsor: Icahn School of Medicine at Mount Sinai Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06689176
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign and date a consent form agreeing to take part in the study.
  • People who are available for the full length of the study and willing to follow all study procedures, including doing twice-daily irrigation (rinsing) of their neobladder or ileal conduit (types of urinary diversion created after bladder removal).
  • People who are male or female and aged 18 or older.
  • People who have been diagnosed with bladder cancer.
  • People whose medical team has determined that removal of the bladder with urinary diversion surgery is the appropriate treatment plan.
  • People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale, meaning they are able to carry out at least some daily activities independently (confirm with trial site).
  • People whose blood test shows a kidney function measurement (serum creatinine) of 1.5 mg/dL or lower.

Who may not be able to join:

  • People who have already had, or are planned to have, a type of urinary diversion other than an ileal conduit or neobladder.
  • People who are pregnant or breastfeeding.
  • People with a known allergy to chlorhexidine or any other component of the Irrisept irrigating system used in this study.
  • People with any serious uncontrolled health condition — such as an active infection, heart failure, unstable chest pain, irregular heartbeat, or a mental health or personal situation — that the study doctor believes would make it difficult to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: John P Sfakianos, MD, Associate Professor of Urology

Phone: (212) 241-0751

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants that have negative urine culture; Proportion of participants with incident symptomatic UTI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov